SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Attention centers on the approaching FDA decision on Capricors deramiocel for Duchenne muscular dystrophy, with traders weighing the companys amended application and longer-term upper-limb data alongside recent FDA discussion of flexibility in rare-disease reviews. Many are bullish and read commercial hiring as a sign of launch preparation, while skeptics stress that approval is uncertain given the earlier negative review and debate over the evidence; some also cite Inovios separate FDA approval as a positive sentiment signal.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

A push to a fresh 52-week high is drawing attention ahead of an expected Q3 earnings update, while traders debate whether the rally reflects business momentum, short-covering, or speculation about an unconfirmed buyout.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Inovios FDA approval of a competing treatment for recurrent respiratory papillomatosis has raised concerns about new competition for Precigens PAPZIMEOS. Traders debate the threat: some see a serious challenge, while others argue Precigen retains an advantage from its commercial head start and full approval, and view the selloff as an overreaction.

Okta, Inc. engages in the provision of an identity management platform for enterprises. The firm operates through the following geographical segments: United States and International. Its products include single sign-on, multi-factor authentication, access gateway, API access management, authentication, adaptive MFA and lifecycle management. The company was founded by Todd McKinnon and J. Frederic Kerrest in 2009 and is headquartered in San Francisco, CA.

Okta Inc - Ordinary Shares - Class A

Okta Inc

Oktas stronger-than-expected quarterly results and raised outlook, alongside growing interest in identity security for AI agents, have driven a sharp rally. Traders are divided between seeing durable cybersecurity demand and warning that the move has outrun the companys growth, with valuation concerns and profit-taking weighing on shares.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that Medicare reimbursement for DefenCath could decline after early 2027 has fueled concerns about pricing and CorMedixs largest revenue driver. Traders are divided: some see the comments as a serious commercial risk, while others argue DaVitas outlook is preliminary and point to CMSs reimbursement estimate as a counterweight.

Mineralys Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing medicines to target diseases driven by abnormally elevated aldosterone. Its clinical-stage product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that are initially developing for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone, including hypertension and chronic kidney disease. The company was founded by Brian Taylor Slingsby on May 31, 2019 and is headquartered in Radnor, PA.

Mineralys Therapeutics Inc

MLYS is under pressure amid concerns that the slow early commercial ramp for AstraZenecas competing hypertension drug could signal a challenging launch and weaker near-term sales prospects for lorundrostat. Traders disagree on whether that undermines Mineralyss commercial outlook, with some emphasizing the upcoming FDA decision and clinical data while others question its ability to compete independently.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins steep selloff and fresh lows ahead of its earnings report are driving attention, with analyst price-target cuts and concerns about advertising demand adding pressure. Traders are split between viewing the decline as excessive given the companys growth and profitability, and worrying that weaker ad-market signals or an earnings disappointment could prolong the slide.

BNB (BNB) is a cryptocurrency . BNB has a current supply of 131,511,396.41. The last known price of BNB is 698.79071116 USD and is down -6.08 over the last 24 hours. It is currently trading on 3523 active market(s) with $4,017,835,584.29 traded over the last 24 hours. More information can be found at https://bnbchain.org/en.

Binance

A reported major Binance security breach, with withdrawals temporarily suspended and billions in crypto reportedly affected, is driving attention to BNB and broader crypto-market concerns. Traders are debating whether the incident threatens trust in Binance and warrants further selling, while others view the selloff as an overreaction; claims of an inside job remain speculation.

Permian Resources Corp. is an oil and natural gas company, which focuses on returns to stakeholders through the responsible acquisition, optimization and development of crude oil and associated liquids-rich natural gas reserves. The company was founded on December 18, 2025 and is headquartered in Midland, TX.

Permian Resources Holdings Inc. - Ordinary Shares - Class A

Permian Resources Corp - Ordinary Shares - Class A

Permian Resources is being discussed amid volatile crude prices and shifting Middle East supply risks, especially tensions and shipping disruptions around the Strait of Hormuz. Traders debate why PR often fails to track oils moves, while some point to the companys production growth, guidance and dividends as support for a longer-term bullish view.

Centrus Energy Corp. engages in the supply of nuclear fuel and services for the nuclear power industry. It operates through the Low-Enriched Uranium (LEU) and Technical Solutions segments. The LEU segment includes various components of nuclear fuel to utilities from its global network of suppliers. The Technical Solutions segment offers advanced engineering, design, and manufacturing services to government and private sector customers, and is deploying advanced nuclear fuel production capabilities to power existing, and next-generation reactors around the world. The company was founded in October 1992 and is headquartered in Bethesda, MD.

Centrus Energy Corp - Ordinary Shares - Class A

Centrus Energy Corp 

Centruss steep selloff is the dominant topic, with traders citing share dilution and the cost and execution risks of expanding enrichment capacity, alongside weakness across nuclear stocks. Bulls point to its strategic U.S. HALEU supply role and government contracts as long-term support, while others question the valuation and whether the decline has further to run.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Arcutis Biotherapeutics, Inc. (ARQT) Reports Next Week: Wall Street Expects Earnings Growth

Arcutis Biotherapeutics (ARQT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) Expected to Beat Earnings Estimates: Should You Buy?

AnaptysBio (ANAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AnaptysBio, Inc. (ANAB) Reports Q2 Loss, Tops Revenue Estimates

AnaptysBio (ANAB) delivered earnings and revenue surprises of +76.09% and +3.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB)

Alphyn Capital on Its Special-Situation Investment: AnaptysBio (ANAB...

GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer

GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

CorMedix (CRMD) delivered earnings and revenue surprises of +11.54% and +7.64%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

GSK's Jemperli Delivers Promising Interim Data in Rectal Cancer

GSK reports positive interim phase II AZUR-1 data as Jemperli meets the primary endpoint in rectal cancer, supporting potential regulatory filings.

Is AnaptysBio (ANAB) Outperforming Other Medical Stocks This Year?

Here is how AnaptysBio, Inc. (ANAB) and Electromed, Inc. (ELMD) have performed compared to their sector so far this year.

Wall Street Analysts See a 38.75% Upside in AnaptysBio (ANAB): Can the Stock Really Move This High?

The consensus price target hints at a 38.8% upside potential for AnaptysBio (ANAB). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

AnaptysBio (ANAB) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

After losing some value lately, a hammer chart pattern has been formed for AnaptysBio (ANAB), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

AnaptysBio Inc

ANAB Stock Falls After Company Sues GSK Unit Tesaro Again, Claims Fresh Breach Of 2014 Deal

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>Anaptys alleges that Tesaro violated the terms of the 2014 deal between the two companies.&nbsp;</li><li>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it.</li><li>A trial is now anticipated in July 2026, and milestone and royalty payments continue to be due to Anaptys during the proceedings.</li></ul><p>AnaptysBio, Inc. (ANAB) said on Friday that it has initiated litigation against GSK unit Tesaro, alleging a breach of the terms of the collaboration agreement between the two companies, inked in March 2014. This renewed battle adds to a fraught relationship between the two companies, with a trial now expected in July next year.</p><p><a href="https://stocktwits.com/symbol/ANAB">ANAB shares</a> dipped 10% in the pre-market session at the time of writing.</p><h2 class="st-heading-2">New Legal Fight</h2><p>Anaptys has<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://ir.anaptysbio.com/news-releases/news-release-details/anaptys-initiates-litigation-against-tesaro-gsk-subsidiary"> requested</a> that the court declare that Anaptys is entitled to all rights and remedies under the collaboration agreement. The company alleged that Tesaro violated exclusivity obligations by participating in past, ongoing, and upcoming governed clinical trials with PD-1 antagonists, a type of immunotherapy, and failed to use commercially reasonable efforts to obtain optimum commercial return for its immunotherapy called Jemperli. A trial is now anticipated in July 2026 and milestone and royalty payments continue to be due to Anaptys during the proceedings.</p><p>The company said that it approached Tesaro to resolve the claims, but Tesaro initiated a lawsuit against it. Tesaro, in turn, alleges that Anaptys breached the agreement between the two companies. Anaptys said that Tesaro’s claims are entirely without merit and that it intends to pursue all appropriate legal remedies against Tesaro.</p><h2 class="st-heading-2">Previous Litigation</h2><p>Anaptys filed a complaint previously against GSK in 2020, alleging that GSK’s planned trial of Zejula in combination with Merck’s Keytruda violated the exclusivity obligations under the 2014 deal.</p><p>The complaint resulted in a settlement that included a cash payment.</p><h2 class="st-heading-2">$100M Stock Repurchase Plan</h2><p>Separately, Anaptys also announced that its Board of Directors has authorized an amended stock repurchase plan under which the company may repurchase up to $100 million of the company’s outstanding common stock. This is in addition to the $6.4 million that remained as of Nov. 20, 2025, under the current $75 million stock repurchase plan.</p><p>The shares may be repurchased from time to time in open market transactions, and the stock repurchase plan will expire on March 31, 2026, the company said.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around ANAB stayed within the ‘neutral’ territory over the past 24 hours while message volume stayed at ‘extremely low’ levels.</p><figure class="image"><img style="aspect-ratio:584/61;" src="data:image/png;base64,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" width="584" height="61" alt="ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits"><figcaption>ANAB’s Sentiment Meter and Message Volume as of 7:05 a.m. ET on Nov. 21, 2025 | Source: Stocktwits</figcaption></figure><p>ANAB stock has nearly tripled this year and gained 78% over the past 12 months.&nbsp;</p><p>Also See: <a href="https://stocktwits.com/news-articles/markets/equity/foxconn-to-pour-up-to-5b-into-us-plants-after-striking-servers-deal-with-openai/cLPMZruREOB">Foxconn To Pour Up To $5B Into US Plants After Striking Servers Deal With OpenAI</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com</i></p>

In this photo illustration an AnaptysBio logo is displayed on a smartphone screen in Athens, Greece on January 13, 2023. (Photo illustration by Nikolas Kokovlis/NurPhoto via Getty Images)

The dispute centers around Tesaro’s participation in PD-1 trials. 

Glaxosmithkline plc - ADR

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Stocktwits

Stocktwits Polls

$ANAB (Anaptys, collects royalties on GSK's cancer drug Jemperli): the FDA approved Jemperli in stage II/III MSI-H/dMMR rectal cancer ahead of its Feb 2027 PDUFA date, with 68% of evaluable patients (98/144) in a sustained 12-month complete response by investigator assessment. By central review, the primary measure, it's 47% so far. Market value ~$1.47B at $49.27 (14:28 ET Oct 19, 2026); cash and investments $164.1M at June 30, 2026. But royalties first repay ~$299M non-recourse Sagard debt, paydown seen 2H 2027. Full data at ESMO Oct 25.

Filecrux

Latest company news, October 19, 2026: GSK says the FDA approved Jemperli under accelerated approval for MSI-H/dMMR locally advanced rectal cancer, ahead of the February 2027 target it had announced. For AnaptysBio any effect would run through the royalty on GSK's net sales, not through cash already received. 
 
AnaptysBio $ANAB Stock: Quimilza PDUFA, Jemperli Royalties and Risks 
Not investment advice. More details in our stock hub.

Merlintrader Trading Pub

📅 CATALYST REMINDER | $ANAB 
October 20 & 25, 2026 — Legal Hearing & Phase 2 Data 
October 20: post-trial hearing in GSK/Tesaro Jemperli litigation (not a judgment date). October 25: AZUR-1 Phase 2 dostarlimab data in locally advanced dMMR/MSI-H rectal cancer at ESMO. 
More details in our hub. 
#ANAB #Biotech #Litigation

Feed

News

Sentiment

Earnings

Fundamentals

Info

ANAB AnaptysBio Inc

Fundamentals

Latest ANAB News